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OBJECTIVE — To compare the efﬁcacy and safety of adding mealtime pramlintide or rapid-
acting insulin analogs (RAIAs) to basal insulin for patients with inadequately controlled type 2
diabetes.
RESEARCH DESIGN AND METHODS — In a 24-week open-label, multicenter study,
113 patients were randomly assigned 1:1 to addition of mealtime pramlintide (120 g) or a
titrated RAIA to basal insulin and prior oral antihyperglycemic drugs (OADs). At screening,
patients were insulin naive or had been receiving 50 units/day basal insulin for 6 months.
The basal insulin dosage was titrated from day 1, seeking fasting plasma glucose (FPG) 70–
100 mg/dl. Pramlintide and an RAIA were initiated on day 1 and week 4, respectively. The
proportion of patients achieving A1C 7.0% without weight gain or severe hypoglycemia at
week 24 was the primary end point.
RESULTS — More pramlintide- than RAIA-treated patients achieved the primary end point
(30 vs. 11%, P  0.018) with a similar dose of basal insulin. Pramlintide and an RAIA yielded
similarmeanSEMvaluesforFPGandA1Cat24weeks(1227vs.1235mg/dland7.2
0.2 vs. 7.0  0.1%, respectively) and similar least squares mean reductions from baseline to end
point (31  6 vs. 34  6 mg/dl and 1.1  0.2 vs. 1.3  0.2%, respectively). RAIAs but
notpramlintidecausedweightgain(4.70.7vs.0.00.7kg,P0.0001).Fewerpatients
reportedmildtomoderatehypoglycemiawithpramlintidethanwiththeRAIA(55vs.82%),but
more patients reported nausea (21 vs. 0%). No severe hypoglycemia occurred in either group.
CONCLUSIONS — In patients taking basal insulin and OADs, premeal ﬁxed-dose pram-
lintide improved glycemic control as effectively as titrated RAIAs. The pramlintide regimen
sometimes caused nausea but no weight gain and less hypoglycemia.
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A
dding basal insulin therapy to oral
agents improves glycemic control
for many patients with type 2 dia-
betes, but up to 50% of patients continue
tohaveA1Cvalues7%(1–5).Persistent
after-meal hyperglycemia is generally ob-
servedinsuchpatients(6).Theusualnext
step in treatment is addition of mealtime
insulin injections, but this approach in-
creases risks of weight gain and hypogly-
cemia (4,6).
Previous studies have shown that de-
fectsinadditiontoinsulindeﬁciencycon-
tribute to after-meal hyperglycemia. Both
insulinandamylinaresecretedby-cells,
and, in individuals with abnormal -cell
function, glucose- and mixed meal–
stimulated secretion of both hormones is
delayed and reduced (7–9). Insulin deﬁ-
ciency impairs suppression of hepatic
glucose production and enhancement of
glucose uptake by tissues that normally
limit postmeal hyperglycemia. Amylin
deﬁciency accelerates gastric emptying,
increases glucagon secretion, and alters
satiety mechanisms (10,11).
Pramlintide, an injectable synthetic
analog of amylin, slows gastric emptying,
attenuates postprandial glucagon secre-
tion, enhances satiety, and reduces food
intake (12–14). Pramlintide is approved
as adjunctive treatment for patients with
diabeteswhousemealtimeinsulinwithor
without oral antihyperglycemic drugs
(OADs) and have not achieved desired
glucose control. Recently, a 16-week,
double-blind, placebo-controlled study
of patients with type 2 diabetes showed
that pramlintide reduces A1C and weight
withoutincreasinginsulin-inducedhypo-
glycemia when added to basal insulin 
OADs without mealtime insulin (15).
Pramlintide may offer an additional
therapeutic option for mealtime use by
patients with type 2 diabetes already us-
ing basal insulin. Rapid-acting insulin an-
alogs (RAIAs) and pramlintide have
differentmechanismsofactionanddiffer-
ent patterns of desired and unwanted ef-
fects. Although both can limit after-meal
hyperglycemia, RAIAs often cause weight
gain and hypoglycemia (6), whereas
pramlintide is associated with weight loss
and nausea (15,16). This study was de-
signed to compare the efﬁcacy and side
effects of pramlintide versus RAIAs when
added to basal insulin to intensify treat-
ment of type 2 diabetes.
RESEARCH DESIGN AND
METHODS— Patients enrolled were
aged18–75years,hadaclinicaldiagnosis
oftype2diabetes,andhadA1C7%and
10% with or without use of any combi-
nation of metformin, thiazolidinedione,
or sulfonylurea OADs. Study participants
were pramlintide naive and either insulin
naive or had used 50 units/day of basal
insulin for 6 months. Inclusion criteria
included BMI 25 and 50 kg/m
2. Fe-
malepatientswereneitherpregnantnorlac-
tating and were postmenopausal or using
birth control. Candidates were excluded if
they adhered poorly to diabetes manage-
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severe hypoglycemia within the last 6
months, or had a history of hypoglycemia
unawareness. Patients with gastroparesis
or those who required medications to al-
tergastricmotilitywereexcluded,aswere
patients using exenatide or sitagliptin,
any antiobesity agents, systemic glu-
cocorticoid agents, or investigational
medications. Patients with eating disor-
ders, a history of bariatric surgery, or plans
to lose weight were excluded, as were pa-
tients with any signiﬁcant medical condi-
tions or advanced diabetes complications.
Ethical considerations
The study protocol was approved by ap-
plicable institutional review boards and
conducted in accordance with the Decla-
ration of Helsinki. All patients provided
written informed consent before study
initiation.
Study design and interventions
This was a randomized, open-label, par-
allel-group, multicenter 24-week study
conducted at 29 centers throughout the
U.S.betweenApril2007andMay2008(a
complete list of the participating investi-
gators can be found in the APPENDIX). After
thescreeningvisit,eligiblepatientsvisited
thestudycenteronday1(baseline)andat
weeks 4, 8, 12, 18, and 24. Scheduled
telephone visits to review self-monitored
glucose measurements and direct insulin
adjustment occurred between visits. Ran-
domassignment1:1topramlintide(Amy-
lin Pharmaceuticals, San Diego, CA) or to
an RAIA (insulin lispro, insulin aspart, or
insulinglulisine)occurredatbaselineand
was centrally generated and stratiﬁed ac-
cording to A1C screening values (9.0%
or 9.0%) and insulin use (insulin naive
or receiving basal insulin at screening).
All patients received insulin glargine
or detemir throughout the study, once or
twice daily. Basal insulin was titrated at
the investigator’s direction weekly or
twice weekly to achieve a fasting plasma
glucose (FPG) concentration of 70–
100 mg/dl, as in the Treat-To-Target
Study (1). Study medication (pramlintide
or an RAIA) was self-administered subcu-
taneously before major meals. Patients in
the pramlintide treatment group received
120 g s.c. before major meals beginning
on day 1 because a prior study demon-
strated no increased risk of hypoglycemia
when ﬁxed-dose pramlintide was added
tobasalinsulin(15).Dosereductionto60
g pramlintide per meal was permitted
for patients with persistent clinically sig-
niﬁcant nausea. Patients randomly as-
signed to an RAIA received only titrated
basal insulin therapy for 4 weeks to avoid
thehypoglycemiariskassociatedwithtitrat-
ing basal insulin and an RAIA simulta-
neously. After 4 weeks, RAIA-randomized
patientsstartedRAIAtherapywith5units
of lispro, aspart, or glulisine before each
meal. Mealtime insulin doses were ad-
justed with investigator guidance by 1–2
units every 3–7 days with the aim of
maintaining glucose concentrations at
70 and 100 mg/dl before the subse-
quentmealor(forthedinnertimedose)at
bedtime. Patients self-monitored blood
glucose daily according to individualized
advice from site investigators. A seven-
point glucose proﬁle consisting of mea-
surementstaken15minbeforeand1.5–2
h after the start of each of the three meals
and at bedtime was completed during the
week before each visit. At each visit,
weight, body circumference, and vital
signs were measured and blood glucose
values were reviewed. Participants were
counseled on adjustment of basal and
mealtime insulin dosage (RAIA group) at
each visit. A1C was measured at all study
visits, and FPG was measured at screen-
ing,baseline,andweeks4,12,and24.No
speciﬁc lifestyle modiﬁcation was ad-
vised; patients were asked to maintain
usual diet and exercise patterns.
Study end points
The primary end point was the propor-
tion of patients achieving the following
prespeciﬁed criteria at week 24: 1) A1C
7.0%, 2) no weight gain from baseline,
and 3) no severe hypoglycemia. Severe
hypoglycemia was deﬁned as an event re-
quiring assistance of another individual
and/or administration of glucagon injec-
tion or intravenous glucose. Secondary
end points included the individual com-
ponentsofthecompositeendpoint,insu-
lin dose, A1C, change in A1C, proportion
of patients reaching A1C 6.5%, FPG,
postprandialglucoseincrements,changes
in weight, changes in waist circumfer-
ence,andadverseeventsincludingthein-
cidence, severity, and time courses of
hypoglycemia and nausea.
Statistical analyses
Asamplesizeof45patientspergroupwas
predictedtoprovide90%powertodetect
a 27% difference in the proportion of pa-
tients achieving the primary end point
(	0.05). Analyses were performed on
patients within the intent-to-treat (ITT)
population including all randomly as-
signed patients receiving at least one dose
of study medication. Missing individual
data were imputed from the last sched-
uled visit (last observation carried for-
ward). Insulin dose was analyzed in the
ITT observed population. Measured val-
ues for insulin dose, A1C, FPG, and
glucoseincrementsarepresentedasarith-
metic mean  SEM.
Fisher’s exact test was used to com-
pare the proportion of patients achieving
the primary end point. The Cochran-
Mantel-Haenszel test that controlled for
A1C at screening was used as a conﬁrma-
tory test. Intergroup comparisons of con-
tinuous changes from baseline were
assessed with ANOVA models including
treatment group, A1C at screening
(9.0%or9.0%),insulintreatmentbe-
fore screening, and baseline value (for pa-
rameters other than A1C). Data were
reported as least squares mean change 
SEM.
RESULTS
Patient disposition, baseline
demographics, and therapies
Of 113 patients randomly assigned, 48
(84%) pramlintide-treated and 50 (89%)
RAIA-treated patients completed the
study (Table 1). One patient in the pram-
lintidegroupwithdrewconsentbeforein-
jecting study medication, resulting in an
ITT population of 56 patients per treat-
ment group. Baseline characteristics were
well matched between groups (Table 1).
Before the study, 46% of patients used
insulin and 91% of patients used at least
one OAD.
Basal insulin dosage increased
steadily throughout the study, resulting
in similar mean doses at week 24: 52  4
units/day (0.48  0.04 unit   kg
1  
day
1) for pramlintide-treated patients
and 57  4 units/day (0.52  0.04 units  
kg
1 day
1)forpatientsintheRAIAarm
(Fig. 1A). After 24 weeks, RAIA-treated
patients administered a mean daily dose
of 37  3 units (0.34  0.03 unit   kg
1  
day
1) of insulin lispro, aspart, or glu-
lisine.Numbersofpatientsinitiatingther-
apywithinsulinlispro,aspart,orglulisine
were 16 (29%), 31 (55%), and 9 (16%),
respectively. To achieve glycemic results
similar to those of the pramlintide group,
patients in the RAIA group used an aver-
age of 80% more insulin (basal  rapid-
acting) at week 24 (94 vs. 52 units,
respectively).
Forty-six participants (82%) contin-
ued to take 120 g pramlintide before
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pants reduced the dosage to 60 g be-
cause of nausea.
Primary end point
The primary composite end point com-
prised several highly desirable goals as-
sessed after 24 weeks of treatment: A1C
7.0%, no weight gain from baseline,
and no severe hypoglycemia (Table 2).
Signiﬁcantly more pramlintide-treated
than RAIA-treated patients achieved this
end point (30 vs. 11%, P  0.018).
Amongthecomponentsofthecomposite,
only the percentage of patients without
weight gain at week 24 differed signiﬁ-
cantly between pramlintide- and RAIA-
treatedpatients(59vs.16%,P0.0001).
No signiﬁcant differences in the fre-
quencyofachievingA1C7.0%orinthe
incidence of severe hypoglycemia were
observed between groups.
Secondary end points
A1C. Mean A1C at 24 weeks was 7.2 
0.2% with addition of pramlintide and
7.00.1%withadditionofanRAIA(Fig.
1B). The least squares mean reduction of
A1C from baseline was 1.1  0.2 for
pramlintide and 1.3  0.2 for RAIA
(P  0.46 between groups). A1C 6.5%
at 24 weeks was achieved by 16 of 56
(29%) of patients treated with pramlin-
tide and by 19 of 56 (34%) of patients
treated with an RAIA (P  0.68 between
groups). A1C values were stable after
week 12 (Fig. 1B).
Weightandwaistcircumference. Asig-
niﬁcant between-group difference in
weight was observed throughout the
study (Fig. 1C). At week 24, mean
weights were 106  3 kg (pramlintide)
versus 109  3 kg (RAIA). Least squares
mean changes in weight from baseline
were 0.0  0.7 kg (pramlintide) versus
4.7  0.7 kg (RAIA) (P  0.0001).
Differences in waist measurements
were consistent with weight differences.
Waist circumferences at week 24 were
115  2 and 120  2 cm for the pram-
lintide and RAIA groups, respectively.
Least squares mean changes in waist cir-
cumference from baseline were 0.6 
0.9and2.20.9cm,respectively(P
0.016).
FPG. Similar basal insulin titration in
both treatment arms resulted in similar
mean FPG concentrations at week 24:
1227mg/dl(pramlintide)and1235
mg/day (RAIA) (Fig. 1D). The least
squares mean change of FPG from base-
line was 31  6 mg/dl (pramlintide)
and 34  6 mg/dl (RAIA) (P  0.65).
An FPG concentration 100 mg/dl was
achieved at week 24 by 17 of 56 (30%) of
pramlintide-treatedand15of56(27%)of
RAIA-treated patients (P  0.83).
Postprandialglucoseincrements. Post-
prandial glucose increments were similar
between treatment groups at week 24
(Fig. 2A). No signiﬁcant difference in the
least squares mean change in postpran-
dial increment from baseline to week 24
was found between treatment groups
(175mg/dl[pramlintide]vs.27
5 mg/dl [RAIA], P  0.17).
Adverse events. The most common ad-
verse events were hypoglycemia and nau-
sea (Fig. 2B). Although no episodes of
severehypoglycemiawereobserved,mild
or moderate hypoglycemia occurred
more frequently than nausea in both
treatment groups and was observed in
more patients treated with RAIAs (82%)
thanwithpramlintide(55%).Hypoglyce-
mic events occurred more frequently in
the pramlintide treatment group in the
ﬁrst 4 weeks but were more common in
the RAIA treatment group from 18 to 24
weeks (Fig. 2C). Nausea was reported
only in the pramlintide group (12 of 56
[21%]), most often early in treatment (10
of 56 patients in the ﬁrst 4 weeks), and
declined over time (Fig. 2D). Two pa-
tients (4%) withdrew from pramlintide
therapy and the study because of nausea.
Eight serious adverse events were re-
ported in six patients during the study:
onepatientinthepramlintidegroup(cor-
onary artery disease) and ﬁve patients in
the RAIA group (coronary artery disease,
congestiveheartfailure,ischemiccerebral
infarction, syncope, noncardiac chest
pain, cellulitis, and biliary dyskinesia).
Table 1—Patient disposition and demographic and clinical characteristics at baseline
Pramlintide RAIA
Disposition
Randomized 57 56
Withdrew before treatment 1 0
Completed 48 50
Withdrew between treatment and week 24 8 6
Reason for withdrawal
Withdrawal of consent 4 2
Adverse event 2 0
Investigator decision 1 0
Protocol violation 0 0
Lost to follow-up 2 4
Baseline demographics
ITT population 56 56
Sex (male/female) 34/22 37/19
Race (Caucasian/other) 48/8 43/13
Age (years) 55  11 54  10
Weight (kg) 108  22 103  18
BMI (kg/m
2) 36  63 6  6
Diabetes duration (years) 10  79  6
A1C (%) 8.2  0.8 8.3  0.8
FPG (mg/dl) 155  40 164  50
OAD use at randomization 50 52
Average number of oral medications per patient 1.9 1.7
Sulfonylurea 34 29
Metformin 36 38
Thiazolidinediones 16 15
Combined drug formulations 5 2
Insulin use before randomization 27 24
Daily basal insulin dose at baseline (units/day) 20  10 24  12
Type of basal insulin initiated after randomization
Insulin glargine q.d. 37 45
Insulin glargine b.i.d. 1 0
Insulin detemir q.d. 18 11
Insulin detemir b.i.d. 0 0
Data are n or means  SD.
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head comparison demonstrated that pre-
meal pramlintide and RAIA have similar
glycemic effects when either agent is
added to titrated basal insulin with or
without an OAD. On average, pramlin-
tide reduced A1C from 8.2 to 7.2%, and
an RAIA reduced A1C from 8.3 to 7.0%
after24weeksoftreatment.Reductionsin
A1C, FPG, and postmeal glycemic incre-
ments were not statistically different
between treatment groups. However,
changes in body weight accompanying
improved glycemic control differed be-
tween treatments. By the most conserva-
tive assessment (the between-treatment
difference of change from baseline in all
patients receiving study medication, last
observation carried forward), RAIA treat-
ment contributed to a 4.7 kg (10.3 lb)
gain compared with pramlintide treat-
ment over 24 weeks. With similar glyce-
mic effects and no severe hypoglycemic
eventswitheithertreatment,thecompos-
iteprimaryendpointfavoredpramlintide
over an RAIA because of the difference in
weight gain.
Other clinical differences between
these therapies are related to unwanted ef-
fects. The incidence of hypoglycemia was
greaterwithanRAIAplusbasalinsulinthan
with pramlintide plus basal insulin (82 vs.
55%). Nausea occurred more frequently
with pramlintide, and two patients (4%)
withdrew from the study. However, as in
other clinical studies, reports of nausea as-
sociated with pramlintide declined steadily
during continued treatment.
This study builds on ﬁndings of a 16-
week study that compared administration
of pramlintide versus placebo during titra-
tionofbasalinsulinwithcontinuationofan
OAD, in which glycemic control improved
more with pramlintide than with placebo
and no severe hypoglycemia was reported
(15).Weightdeclinedameanof1.6kgwith
pramlintide but increased 0.7 kg with pla-
cebo. The larger absolute body weight dif-
ference between groups in this study is
probably due to RAIA-associated weight
gain.
The potential clinical importance of
weight gain associated with treatment for
hyperglycemia has been studied for many
years and remains controversial. An unfa-
vorable relationship between adiposity
and a variety of medical outcomes, in-
cluding cardiovascular disease, is well
established (17,18). Recently, an obser-
Table 2—Primary end point
Pramlintide RAIA
Fisher’s exact
test P value
n 56 56
Patients achieving composite end point* 17 (30) 6 (11) 0.018
Individual end points
Patients achieving A1C 7.0% at week 24 27 (48) 34 (61) 0.25
Patients with no weight gain at week 24 33 (59) 9 (16) 0.0001
Incidence of severe hypoglycemia 0 (0) 0 (0) NS
Data are n (%). *Composite end point: A1C 7.0% at week 24 with no weight gain and no severe hypo-
glycemia. NS, not signiﬁcant.
Figure1—A:Meanchangesininsulindosageoverthecourseofthetrial.Solidsquares,unbrokenlinebasalinsulininthepramlintidegroup.Open
triangles,unbrokenlinebasalinsulinintheRAIAgroup.Opencircles,brokenlinetotalinsulin(basalplusmealtime)intheRAIAgroup.B:Mean
A1C at each visit. Solid squares  pramlintide; open circles  RAIA. C: Least squares mean weight changes over time with the last observation
carried forward. Solid squares  pramlintide; open circles  RAIA. ***P  0.001; **P  0.01. D: Mean fasting plasma glucose over time. Solid
squares  pramlintide; open circles  RAIA. LOCF, last observation carried forward; LS, least squares.
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4,900 patients with
type 2 diabetes showed a 13% increase in
risk for fatal or nonfatal coronary heart
disease with each 1-unit increase of BMI
over 
6 years (19). Furthermore, evi-
dence suggests that intended weight re-
duction reduces cardiovascular risk
factors (20) and mortality (21). However,
direct evidence that weight gain associ-
ated with insulin treatment is harmful is
lacking. Notably, at the end of 10 years of
randomized treatment, the U.K. Prospec-
tive Diabetes Study (UKPDS) showed a
marginally signiﬁcant reduction of myo-
cardial infarction (16%, P  0.052) with
insulin or sulfonylurea treatment com-
pared with dietary treatment, despite
greater weight gain. Follow-up after ces-
sation of randomized treatment showed
persistence of the difference over time,
and the advantage of insulin or sulfonyl-
urea became statistically signiﬁcant with
more events (15%, P  0.01) (22,23).
Other ﬁndings indirectly suggest that
avoiding weight gain and hypoglycemia
while improving glycemic control may
provide cardiovascular beneﬁt. In a study
embedded in the UKPDS, treatment of
obese patients with metformin, which is
not associated with weight gain or hypo-
glycemia, reduced the incidences of myo-
cardial infarction and all-cause mortality
(23). Similar trends were shown in an-
other study with acarbose, an antihyper-
glycemic agent that also does not cause
weightgainorhypoglycemia(24).Incon-
trast, the Action to Control Cardiovascu-
lar Risk in Diabetes (ACCORD) trial,
which compared intensive versus standard
glycemic control strategies associated with
weight gain and hypoglycemia, was
stopped early because of higher all-cause
mortality in the intensive arm, despite a
1.1% lower A1C in this group (25). Poten-
tial underlying mechanisms include the
doubled occurrence of weight gain 10 kg
with intensive treatment, the threefold in-
crease of severe hypoglycemia, or both.
This study had several limitations. It
wasasmallstudy,poweredtoaddressthe
composite primary outcome but not sep-
arate clinical outcomes, and the open-
label design allows the possibility of
unintendedbias.The4-weekdelayinini-
tiating an RAIA to avoid insulin-induced
hypoglycemia from simultaneous initia-
tion of basal and rapid-acting insulin was
alsoalimitation.Becauseofthedifference
in the timing of RAIA initiation, the po-
tential for weight gain in the RAIA group
may be underestimated at week 24, but
glycemic outcomes at week 24 did not
seemtobeaffected,asinsulindoses,A1C,
and FPG in both treatment groups stabi-
lized after 12 weeks, well before the
study’s end. The incidence of nausea ac-
companying initiation of pramlintide
(
20%)wasconﬁrmedasaleadingdraw-
back of starting treatment at 120 g. Both
nausea associated with pramlintide and hy-
poglycemia/weight gain associated with an
RAIA might have been mitigated by more
gradual titration. The small imbalance in
use of detemir as the basal insulin (18 with
pramlintide and 11 with an RAIA) is of un-
certain signiﬁcance. Differences in overall
costs between the pramlintide and RAIA
regimens might exist but are not addressed
in this study of efﬁcacy and safety.
Overall, these ﬁndings support the
role of mealtime pramlintide as a poten-
tial alternative to RAIAs for patients using
basal insulin treatment with or without
OADs who are not achieving glycemic
goals. Longer-term studies to evaluate
cardiovascular and microvascular out-
comes of controlling after-meal hyper-
Figure 2—A: Postprandial glucose increments from before to after meals at 24 weeks. Black bars  pramlintide; white bars  RAIA. B: Incidence and
severity of hypoglycemia and nausea in patients treated with pramlintide or RAIA in addition to basal insulin. White bar  mild; striped bar  mild or
moderate; cross-hatched bar  moderate; black bar  severe. C: The rate of hypoglycemia (events/week) over the course of the study with RAIA and
pramlintidetreatment.Blackbarspramlintide;whitebarsRAIA.D:Numberofpatientsreportingnauseaovertimeduringtreatmentwithpramlintide.
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hypoglycemia would be helpful to inform
clinical treatment decisions for patients
with type 2 diabetes.
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